Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CHR 6494 TFA 是一种选择性 haspin 抑制剂,IC50值为 2 nM,可抑制组蛋白 H3T3 的磷酸化。它诱导黑色素瘤、乳腺癌等肿瘤细胞凋亡,可研究癌症。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 897 | 现货 | ||
2 mg | ¥ 1,290 | 现货 | ||
5 mg | ¥ 1,830 | 现货 | ||
10 mg | ¥ 2,990 | 现货 | ||
25 mg | ¥ 4,950 | 现货 | ||
50 mg | ¥ 6,910 | 现货 | ||
100 mg | ¥ 9,490 | 现货 | ||
500 mg | ¥ 18,800 | 待询 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,990 | 现货 |
产品描述 | CHR-6494 TFA is a potent haspin inhibitor, with an IC50 of 2 nM. It inhibits histone H3T3 phosphorylation. CHR-6494 TFA induces the apoptosis of cancer cells, including melanoma and breast cancer. CHR-6494 TFA can be used in the research of cancer |
靶点活性 | Haspin:2 nM (IC50) |
体外活性 | Administration of CHR-6494 (TFA; 0-10-5?nM; 72 hours) dose-dependently inhibits the growth of cancer cells, such as HCT-116, HeLa, MDA-MB-231, and Wi-38 cells, with an IC50s of 500?nM, 473?nM, 752?nM and 1059 nM, respectively[1]. Administration of CHR-6494 (TFA; 500 nM) produces a mitotic catastrophe with abnormal morphology of the mitotic spindle and centrosome amplification, and upregulates the spindle assembly checkpoint protein BUB1 and the marker of mitotic arrest cyclin B1[1]. |
体内活性 | Administration of CHR-6494 (TFA; 50?mg/kg; i.p. in two cycles of five consecutive days for 15 days) inhibits the growth of tumor and no obvious body weight change is observed in nude mice bearing HCT-116 human colorectal cancer cells[1]. |
分子量 | 406.36 |
分子式 | C18H17F3N6O2 |
CAS No. | 1458630-17-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/mL (135.35 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.4609 mL | 12.3044 mL | 24.6087 mL | 61.5218 mL |
5 mM | 0.4922 mL | 2.4609 mL | 4.9217 mL | 12.3044 mL | |
10 mM | 0.2461 mL | 1.2304 mL | 2.4609 mL | 6.1522 mL | |
20 mM | 0.123 mL | 0.6152 mL | 1.2304 mL | 3.0761 mL | |
50 mM | 0.0492 mL | 0.2461 mL | 0.4922 mL | 1.2304 mL | |
100 mM | 0.0246 mL | 0.123 mL | 0.2461 mL | 0.6152 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
CHR-6494 TFA 1458630-17-5 Others CHR-6494 inhibit apoptosis Haspin Kinase NRAS mutant melanoma cells CHR 6494 mitotic catastrophe Inhibitor mice CHR6494 cancer cells CHR6494 TFA BRAFV600E mutant melanoma cells CHR 6494 TFA inhibitor